Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study

Lyon, Gholson J., Samar, Stephanie, Jummani, Rahil, Hirsch, Scott, Spirgel, Arie, Goldman, Rachel, Coffey, Barbara J. (2009) Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study. Journal of Child and Adolescent Psychopharmacology, 19 (6). pp. 623-633. ISSN 1557-8992

[thumbnail of Paper]
Preview
PDF (Paper)
Lyon GJ Journal of Child and Adolesc Psychopharm 2009.pdf - Published Version

Download (174kB) | Preview
URL: http://www.ncbi.nlm.nih.gov/pubmed/20035580
DOI: 10.1089/cap.2009.0035

Abstract

The aim of this study was to conduct a prospective safety and tolerability study of aripiprazole for the treatment of tics in children and adolescents with Tourette's disorder (TD).Eleven subjects (10 males) with TD (age 9-19 years, mean 13.36, standard deviation [SD] 3.33) who did not respond or were unable to tolerate previous tic medication were treated with aripiprazole in an open-label, flexible-dosing study over 10 weeks. Tic severity was rated using the Yale Global Tic Severity Scale (YGTSS) and the Clinical Global Impressions Scale for tics (CGI-Tics) at baseline and at follow-up.The mean (+/-SD) daily dose for aripiprazole was 4.5 +/- 3.0 mg. Mean (+/-SD) YGTSS Global Severity scores reduced from 61.82 +/- 13.49 at baseline to 33.73 +/- 15.18 at end point; mean YGTSS total tic scores reduced from 28.18 +/- 7.74 at baseline to 16.73 +/- 7.54 at end point. Mean (+/-SD) CGI-Tic severity scores reduced from 4.45 +/- 0.52 (moderate-marked) at baseline to 3.18 +/- 0.60 (mild) at end point. On the CGI-Tic improvement scale, 10 (91%) subjects achieved 1 ("very much improved") or 2 ("much improved") at end point. Most common adverse effects included appetite increase and weight gain in 5 subjects, mild extrapyramidal effects in 7 subjects, and headaches and tiredness/fatigue in 7 subjects; 1 subject experienced akathisia and muscle cramps.Aripiprazole appears to be a safe and tolerable treatment in children and adolescents with TD that appears to reduce tics; it should be further investigated as a treatment option in controlled trials.

Item Type: Paper
Uncontrolled Keywords: Adolescent Antipsychotic Agents Body Weight Child Dose-Response Relationship, Drug Female Humans Male Piperazines Prolactin Psychiatric Status Rating Scales Quinolones Severity of Illness Index Tics Tourette Syndrome Treatment Outcome Young Adult
Subjects: diseases & disorders > mental disorders
CSHL Authors:
Communities: CSHL labs > Lyon lab
Depositing User: Matt Covey
Date: 2009
Date Deposited: 10 Dec 2012 20:14
Last Modified: 10 Dec 2012 21:11
PMCID: PMC2861961
URI: https://repository.cshl.edu/id/eprint/26293

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving